510(k) Program, Companion Dx Among Top FDA Guidance Priorities For FY 2014
This article was originally published in The Gray Sheet
CDRH says it plans to release the 510(k) program final guidance as well as the anticipated in vitro companion diagnostic final guidance next year. The device center has divided the 22 forthcoming guidance documents into an “A-list” and a “B-list,” based on its priorities and allocated resources.
You may also be interested in...
The device center issued its standard "A list" and "B list" guidance priorities for fiscal year 2015, and unveiled plans to systematically reassess published guidance documents and seek technical feedback on future guidance topics.
The agency tells direct-to-consumer genetic testing company 23andMe in a strongly-worded warning letter that it should immediately stop marketing its Personal Genome Service until it can gain clearance. The firm says it will address the agency’s concerns.
FDA tells direct-to-consumer genetic testing company 23andMe that it should immediately stop marketing its Personal Genome Service in a strongly worded, lengthy warning letter that experts say could provide guidance across the sector. The firm says it will address the agency’s concerns.